Dermatology - Global Oncology Academy

1-16 of 28

Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
CME/CE
Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
Cem Akin, MD, PhD
0.25 credits
- Cem Akin, MD, PhD
0.25 credits
Teledermatology Enables Earlier Diagnosis of Cutaneous Squamous Cell Carcinoma
Teledermatology Enables Earlier Diagnosis of Cutaneous Squamous Cell Carcinoma
Project Oncology®
Teledermatology Enables Earlier Diagnosis of Cutaneous Squamous Cell Carcinoma
Smoking Status Predicts Worse Survival in Non-Melanoma Skin Cancer
Smoking Status Predicts Worse Survival in Non-Melanoma Skin Cancer
Project Oncology®
Smoking Status Predicts Worse Survival in Non-Melanoma Skin Cancer
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
CME/CE
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Mariana C. Castells, MD, PhD; Tsewang Tashi, MD
0.25 credits
- Mariana C. Castells, MD, PhD
- Tsewang Tashi, MD
0.25 credits
Comparing Photodynamic Therapy Approaches in Basal Cell Carcinoma
Comparing Photodynamic Therapy Approaches in Basal Cell Carcinoma
AudioAbstracts
Comparing Photodynamic Therapy Approaches in Basal Cell Carcinoma
Ryan Quigley
- Ryan Quigley
Cosibelimab Delivers Durable Responses in Advanced CSCC
Cosibelimab Delivers Durable Responses in Advanced CSCC
Project Oncology®
Cosibelimab Delivers Durable Responses in Advanced CSCC
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Project Oncology®
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
AudioAbstracts
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
Ryan Quigley
- Ryan Quigley
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Hussein Tawbi, MD, PhD; Paolo A. Ascierto, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD; Paolo A. Ascierto, MD
1.00 credit 10 episodes
- John M. Kirkwood, MD
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 credit 10 episodes
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
MinuteCE®
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Sapna Patel, MD; John M. Kirkwood, MD
1.00 program credit
- Sapna Patel, MD
- John M. Kirkwood, MD
1.00 program credit
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Hussein Tawbi, MD, PhD; Sapna Patel, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit

Prev
1
2
Next

1/2